drugset / Trial / NCT07325630
Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study designed to evaluate the safety and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) or S-1 and oxaliplatin (SOX) in perioprative treatment of locally advanced MHC-II-negative gastric and gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2025-11-03
- Primary completion
- 2026-05-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI363 | Protein / enzyme biologic | — | — |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Background | S-1 | Small molecule | 40 mg | Oral |
| Background | S-1 | Small molecule | 60 mg | Oral |
Indications
No indication recorded.